via Perelman School of Medicine
Promising results in animal models help pave the way for clinical trials
An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, and thus might serve one day as a general preventative measure against future flu pandemics, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
The “multivalent” vaccine, which the researchers describe in a paper published today in Science, uses the same messenger ribonucleic acid (mRNA) technology employed in the Pfizer and Moderna SARS-CoV-2 vaccines. This mRNA technology that enabled those COVID-19 vaccines was pioneered at Penn. Tests in animal models showed that the vaccine dramatically reduced signs of illness and protected from death, even when the animals were exposed to flu strains different from those used in making the vaccine.
“The idea here is to have a vaccine that will give people a baseline level of immune memory to diverse flu strains, so that there will be far less disease and death when the next flu pandemic occurs,” said study senior author Scott Hensley, PhD, a professor in of Microbiology at in the Perelman School of Medicine.
Hensley and his laboratory collaborated in the study with the laboratory of mRNA vaccine pioneer Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research and Director of Vaccine Research at Penn Medicine.
Influenza viruses periodically cause pandemics with enormous death tolls. The best known of these was the 1918-19 “Spanish flu” pandemic, which killed at least tens of millions of people worldwide. Flu viruses can circulate in birds, pigs, and other animals, and pandemics can start when one of these strains jumps to humans and acquires mutations that adapt it better for spreading among humans. Current flu vaccines are merely “seasonal” vaccines that protect against recently circulating strains, but would not be expected to protect against new, pandemic strains.
The strategy employed by the Penn Medicine researchers is to vaccinate using immunogens—a type of antigen that stimulates immune responses—from all known influenza subtypes in order to elicit broad protection. The vaccine is not expected to provide “sterilizing” immunity that completely prevents viral infections. Instead, the new study shows that the vaccine elicits a memory immune response that can be quickly recalled and adapted to new pandemic viral strains, significantly reducing severe illness and death from infections.
“It would be comparable to first-generation SARS-CoV-2 mRNA vaccines, which were targeted to the original Wuhan strain of the coronavirus,” Hensley said. “Against later variants such as Omicron, these original vaccines did not fully block viral infections, but they continue to provide durable protection against severe disease and death.”
The experimental vaccine, when injected and taken up by the cells of recipients, starts producing copies of a key flu virus protein, the hemagglutinin protein, for all twenty influenza hemagglutinin subtypes—H1 through H18 for influenza A viruses, and two more for influenza B viruses.
“For a conventional vaccine, immunizing against all these subtypes would be a major challenge, but with mRNA technology it’s relatively easy,” Hensley said.
In mice, the mRNA vaccine elicited high levels of antibodies, which stayed elevated for at least four months, and reacted strongly to all 20 flu subtypes. Moreover, the vaccine seemed relatively unaffected by prior influenza virus exposures, which can skew immune responses to conventional influenza vaccines. The researchers observed that the antibody response in the mice was strong and broad whether or not the animals had been exposed to flu virus before.
Hensley and his colleagues currently are designing human clinical trials, he said. The researchers envision that, if those trials are successful, the vaccine may be useful for eliciting long-term immune memory against all influenza subtypes in people of all age groups, including young children.
“We think this vaccine could significantly reduce the chances of ever getting a severe flu infection,” Hensley said.
In principle, he added, the same multivalent mRNA strategy can be used for other viruses with pandemic potential, including coronaviruses.
The Latest Updates from Bing News
Go deeper with Bing News on:
- VIDO scientists are working on new foot rot vaccine
Researchers at the Vaccine and Infectious Disease Organization (VIDO) are working on developing a single-shot vaccine that will provide broader protection against foot rot in beef and dairy cattle.
- The FDA says get used to COVID-19 vaccine boosters
By Laura Baisas | Published Jan 27, 2023 9:00 AM On Thursday, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee unanimously voted to support a ...
- Vaccines Market is expected to hold a value of US$ 42.7 billion in 2023
Pages Report] The global vaccines market size is expected to reach US$ 120 Bn by 2032, growing at a 10% CAGR over the forecast period. The advent of existing and re-emerging infectious diseases, ...
- New vaccine platform could ease development, delivery of antigens
By repurposing one of the human body's natural cargo transports, a Harvard-Nebraska team has developed a vaccine platform that could curb certain engineering challenges, storage demands and side ...
- Q&A: New vaccine recommendations for COVID-19
A recent modeling study by Dr. Townsend and colleagues regarding optimal timing for future COVID-19 vaccinations in preventing severe infection was cited by the FDA's Vaccines and Related ...
Go deeper with Bing News on:
mRNA flu vaccine
- An Even Deadlier Pandemic Could Soon Be Here
As the world is just beginning to recover from the devastation of Covid-19, it is facing the possibility of a pandemic of a far more deadly pathogen. Bird flu — known more formally as avian influenza ...
- HealthWatch: mRNA – New Flu Shot on the Way?
Scientists who developed the COVID-19 vaccine used a new technology called mRNA, or messenger RNA. Now, researchers at Yale University are building on that ...
- New reassessments of how clinical trials can and should be conducted
Nebuchadnezzar II, King of Babylon, Sumer, Akkad and all of the universe, decided that a diet consisting entirely of meat and wine ensured good health, and so ordered his subjects to eat nothing more ...
- Global RNA Vaccine Advances Research Report 2022: Overcoming RNA Vaccine Manufacturing Bottlenecks to Meet Increased Demand
The "Advances and Growth Opportunities in RNA Vaccines" report has been added to ResearchAndMarkets.com's offering.
- Tripledemic Rouses Vaccine Developers and Variant Trackers
Three major respiratory viruses—respiratory syncytial virus, seasonal influenza, and COVID-19—are surging at once, prompting a determined scientific response.